Sponsor:
American Federation of Medical Synergetics
Code:
NCT03222375
Conditions
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Eligibility Criteria
Sex: All
Age: 0 - 21
Healthy Volunteers: Not accepted
Interventions
SQUED™ series 28.1 home-use
Brief summary:
Conditions
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Study ID
NCT03222375
Start date
Sep 26, 2017
Status verified date
Nov, 2017
Completion date
Dec, 2027
Anticipated
Primary completion date
Sep, 2022
Anticipated
Eligibility Criteria
Sex: All
Age: 0 - 21
Healthy Volunteers: Not accepted
Enrollment
80 participants
Anticipated
Arms
Autism
Interventions
SQUED™ series 28.1 home-use
Primary outcome measure
Central contacts
Locations
World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS
Recruiting
Louisville, Kentucky, United States, 40228
Contacts
Sponsor
American Federation of Medical Synergetics
Last update posted
Nov 28, 2017
Last verified
Nov, 2017
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by American Federation of Medical Synergetics on 2017-11-28.